Skip Navigation



Carcinogenesis Advance Access published online on March 28, 2008
Carcinogenesis, doi:10.1093/carcin/bgn081
This Article
Right arrow Advance Access manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chen, Y.-C.
Right arrow Articles by Hunter, D. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Y.-C.
Right arrow Articles by Hunter, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Sequence variants of elaC homolog 2 (E. coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study

Yen-Ching Chen1,2, Edward Giovannucci1,3, Peter Kraft4 and David J. Hunter1,4

1 Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
2 Research Center for Genes, Environment, and Human Health, and Graduate Institute of Epidemiology, College of Public Health, National Taiwan University
3 Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
4 Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA

Address correspondence to Yen-Ching Chen, Channing Laboratory, 181 Longwood Avenue, Boston, MA, 02115, USA. Telephone: (617) 525-2279. Fax: (617) 525-2008. E-mail: karen.chen{at}channing.harvard.edu

Background. Two non-synonymous single nucleotide polymorphisms (SNPs), Ser217Leu and Ala541Thr, in the elaC homolog 2 (E. coli) (ELAC2) gene have been related to prostate cancer risk in previous studies, though with inconsistent results. The association of ELAC2 haplotypes with prostate cancer risk has not yet been explored. We assessed whether sequence variants in ELAC2 were associated with the risk of total or aggressive prostate cancer. Methods. In a nested case-control design within the Health Professionals Follow-Up Study, we identified 659 participants with prostate cancer diagnosed after they provided a blood specimen in 1993 and before January 2000. Controls were 656 age-matched men without prostate cancer who had had a prostate-specific antigen test after providing a blood specimen. We genotyped 8 tagging SNPs in ELAC2 to test for association between sequence variances in ELAC2 and prostate cancer. Results. No individual SNP (including Ser217Leu) was associated with the risk of prostate cancer. Ala541Thr is a rare SNP in this population. One common haplotype (hap4) was statistically significantly associated with an increased risk of prostate cancer [odds ratio (OR) = 1.39, 95% CI = 1.05-1.85)]. Two common promoter SNPs and three common haplotypes were statistically significantly associated with aggressive prostate cancer (carriers vs. non-carriers, snp2: OR = 1.43, snp3: OR = 0.69; hap1: OR = 1.47, hap2: OR = 0.72, hap4: OR = 1.51, global P-value for all common haplotypes = 0.11). Conclusion. Common SNPs and haplotypes of ELAC2 were associated with risk of aggressive prostate cancer

Key Words: ELAC2 • prostate cancer • SNP • haplotype

Received November 6, 2007; revised March 6, 2008; accepted March 17, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.